Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Receivables: 2018-2024

Historic Change in Receivables for Aclaris Therapeutics (ACRS) over the last 7 years, with Dec 2024 value amounting to $20,000.

  • Aclaris Therapeutics' Change in Receivables fell 16.67% to -$56,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$131,000, marking a year-over-year decrease of 23.58%. This contributed to the annual value of $20,000 for FY2024, which is 110.75% up from last year.
  • As of FY2024, Aclaris Therapeutics' Change in Receivables stood at $20,000, which was up 110.75% from -$186,000 recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Change in Receivables peaked at $20,000 during FY2024, and registered a low of -$4.9 million during FY2020.
  • Its 3-year average for Change in Receivables is -$101,667, with a median of -$139,000 in 2022.
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 705.44% in 2020, then surged by 110.75% in 2024.
  • Aclaris Therapeutics' Change in Receivables (Yearly) stood at -$4.9 million in 2020, then skyrocketed by 96.96% to -$149,000 in 2021, then climbed by 6.71% to -$139,000 in 2022, then tumbled by 33.81% to -$186,000 in 2023, then spiked by 110.75% to $20,000 in 2024.